Skip to main content
. 2022 Sep 15;14(9):1954. doi: 10.3390/pharmaceutics14091954

Figure 3.

Figure 3

Rational structural modification of the reported pyridopyrazinone-based derivatives as PDE5 inhibitors. The orientation of the terminal groups is modified structurally. In the reported inhibitors, pyridopyrazinone scaffold is designed to be the central motif. In the tested compounds, the pyridopyrazinone ring is functioning as one of binding motifs.